Canada Adult Vaccines Market Overview, 2031

Market performance in Canada’s adult vaccines sector continues to rise, supported by strong public health priorities, growing immunization awareness among adults, and expanded recommendations following lessons from the pandemic era. The product scope now includes influenza, pneumococcal, shingles, hepatitis A/B, HPV for older groups, tetanus/diphtheria/pertussis boosters, travel vaccines, and immunizations for high-risk or immune-compromised adults, marking a major evolution from earlier decades when vaccination programs focused almost exclusively on children. Over time, the market has advanced through improved biotechnology, including mRNA platforms, next-generation adjuvants, nanoparticle formulations, recombinant protein vaccines, and thermostable technologies that reduce dependence on ultra-cold storage. Digital tools such as electronic immunization records, automated reminders, pharmacy based e-booking, and data driven surveillance have also strengthened accessibility and compliance. Core components of the market include vaccine manufacturers, biologics R&D hubs, contract manufacturing and fill-finish facilities, cold-chain logistics providers, provincial procurement systems, pharmacies, hospitals, physicians, and occupational-health immunizers. Key drivers are aging demographics, rising chronic diseases, workplace requirements, stronger travel vaccination demand, and public communication campaigns are increasing adult engagement and broadening the eligible population. Regulatory oversight involves Health Canada approvals, GMP compliance, NACI recommendations, provincial funding decisions, lot-release testing, and continuous pharmacovigilance, supported by stringent safety, labelling, and distribution rules. Challenges remain in vaccine hesitancy, uneven uptake among rural and Indigenous populations, high development and storage costs, and supply chain pressure for specialized refrigeration and timed deliveries. Government initiatives such as expanded pharmacy vaccination authority, targeted regional campaigns, public insurance for selected vaccines, and investment in domestic biomanufacturing continue to shape access and adoption. Consumer behaviour reflects growing risk awareness, preventive health culture, and trust in pharmacist-led immunization, positioning adult vaccines as a key sub segment within Canada’s broader pharmaceutical and immunization ecosystem.

According to the research report, "Canada Adult Vaccines Overview, 2031," published by Bonafide Research, the Canada Adult Vaccines is anticipated to grow at more than 6% CAGR from 2026 to 2031.Canada’s adult vaccines market is shaped by strong public health infrastructure and consistent nationwide demand, allowing several local players to build meaningful positions alongside global firms. Key contributors include Medicago in Québec, recognized for pioneering plant-based vaccine platforms; AbCellera and Precision NanoSystems in Vancouver, which support antibody discovery, mRNA formulation, and delivery-system development; and McKesson Canada, Accuristix, and BioScript Solutions, which anchor distribution through advanced cold-chain logistics and pharmacy-level reach. These companies differentiate through localized R&D, rapid regulatory alignment with Health Canada, specialized biologics capabilities, and region focused distribution models. Their business strategies typically revolve around provincial procurement contracts, CDMO services, collaborations with hospitals and pharmacies, and technology-focused manufacturing partnerships. Market trends highlight increasing reliance on mRNA, recombinant, and adjuvanted vaccines, expanding immunization for influenza, shingles, pneumococcal disease, HPV, and hepatitis, and growing emphasis on adult and senior preventive care. Opportunities emerge in booster programs, travel vaccination, telehealth enabled reminders, and strengthening domestic vaccine self-sufficiency. Marketing primarily occurs through pharmacist-led awareness drives, provincial campaigns, biotech expos, and evidence-driven communication strategies. Sales channels span hospitals, clinics, travel health centres, employer wellness programs, and pharmacies, with private market pricing averaging CAD 40–60 for influenza, CAD 120–180 for hepatitis and pneumococcal, CAD 170–200 per HPV dose, and CAD 150–250 for shingles, subject to provincial reimbursement. New entrants face obstacles including high capital needs, stringent GMP and Health Canada approvals, cold-chain requirements, and entrenched brand trust. Substitutes are minimal, though wellness preferences can influence consumer decisions. Canada’s supply chain integrates biologics R&D, controlled environment manufacturing, rigorous testing, cold-chain logistics, and coordinated provincial distribution, supporting a stable and innovation-oriented adult vaccines ecosystem.

Segmentation of the adult conjugate vaccines market by type highlights the functional and strategic differences between monovalent and multivalent conjugate vaccines, each serving distinct epidemiological and immunization needs across Canada’s adult population. Monovalent conjugate vaccines target a single pathogen or serotype and are typically used when a specific infectious strain poses higher clinical risk or when immunization programs aim to build focused, high-quality immunity with minimal antigen load. In Canada, monovalent formulations are commonly used in booster schedules, outbreak-specific responses, and high-risk adult groups such as seniors, immunocompromised individuals, travellers, and those with chronic diseases. Their advantages include simplified dosing, lower reactogenicity, and strong immunogenic profiles, making them valuable for targeted protection against pathogens like meningococcal serogroup C or specific pneumococcal serotypes. On the other hand, multivalent conjugate vaccines combine several serotypes or antigens within one formulation and hold a significant share of adult immunization due to their broader coverage. These vaccines are widely used in routine adult schedules, workplace immunization drives, and long-term preventive programs because they reduce the need for multiple injections and provide comprehensive protection against diverse circulating strains. In Canada, multivalent products such as pneumococcal conjugate vaccines (PCV13, PCV15, PCV20) and quadrivalent meningococcal conjugate vaccines are preferred in older adults and high-exposure groups where strain diversity is greater. Their adoption is supported by evolving surveillance data, recommendations from the National Advisory Committee on Immunization (NACI), and provincial reimbursement strategies aimed at reducing hospitalization and healthcare burden. Both monovalent and multivalent segments respond to factors such as strain prevalence, immune response durability, cost-effectiveness evaluations, and procurement decisions within public health programs as the market continues to adjust to shifting adult disease patterns in Canada.

Categorizing the Canadian adult vaccines market by disease area reveals clear distinctions in demand patterns, immunization priorities, and public health focus across multiple vaccine-preventable illnesses. Varicella vaccines are primarily administered to adults who lack natural immunity or have not been vaccinated in childhood, with demand driven by workplace requirements, healthcare worker mandates, and travel related immunization needs. Human Papillomavirus (HPV) vaccines represent one of the fastest-growing segments, as adults increasingly seek protection against HPV related cancers; expanded age approvals and strong awareness campaigns continue to widen uptake among both men and women. Measles vaccines remain essential due to periodic outbreaks linked to declining childhood coverage and international travel, prompting booster recommendations for adults without documented immunity. Mumps and rubella vaccines maintain steady demand within combination formulations (such as MMR), often required for university admissions, immigration procedures, and employment in healthcare and childcare settings. Pneumococcal disease vaccines hold a dominant share in adult immunization, especially among older adults and individuals with chronic illnesses, as conjugate and polysaccharide vaccines reduce severe outcomes like pneumonia, bacteraemia, and meningitis, shifting NACI guidelines and improved multivalent formulations continue to shape this segment. The others category includes vaccines against diseases such as hepatitis A/B, influenza, meningococcal disease, shingles, and travel-related infections, each influenced by population ageing, chronic disease prevalence, workplace mandates, global mobility, and province-specific reimbursement programs. Across disease segments, uptake is shaped by changing epidemiology, evolving adult booster schedules, increasing employer-driven immunization requirements, and heightened health awareness following recent global health disruptions, collectively steering demand across Canada's adult vaccines landscape.

Considered in this report
•Historic Year: 2020
•Base year: 2025
•Estimated year: 2026
•Forecast year: 2031



Aspects covered in this report
• Canada Adult Vaccines Market Outlook with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top-profiled companies
• Strategic recommendation

By Disease
• Varicella
• Human Papilloma Virus
• Mumps and Rubella
• Measles
• Pneumococcal Disease
• Others

By Types
• Monovalent Conjugate Vaccines
• Multivalent Conjugate Vaccines